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Background and aims: The Raptopoulos computed tomography (CT) grading system of pancreatico-
biliary cancers was conceived to predict resectability based on tumour involvement of critical vasculature.
The aim of the present study was to investigate the relationship between CT grade, resectability, margin
status and survival after pancreatic resection.
Methods: Patients with presumed pancreaticobiliary malignancy and a pancreas protocol computed
tomography angiogram (CTA) who underwent attempted curative resection from October 2001 and
August 2008 were identified. The relationship between radiographical involvement of critical vasculature,
according to a five-point scale, and ultimate resectability, margin status and survival was assessed.
Results: Overall, 276 (70.2%) out of 393 patients were resectable. The proportion of patients who were
unresectable at laparotomy increased as CT grade escalated; 41/250 (16.4%) CT Grade 0, 16/55 (29.1%)
CT Grade 1, 33/55 (60%) CT Grade 2, 27/33 CT Grade 3, P < 0.001. Local invasion or vascular
involvement was the reason for unresectability in 14/41, 12/16, 23/33, 16/27 patients with CT Grade 0–3,
respectively. A R0 resection was achieved in 84/131 patients with pancreatic adenocarcinoma and varied
significantly by CT grade, P = 0.021. Significant predictors of survival were age (P < 0.0001), resectability
(P < 0.0001) and diagnosis (P < 0.009).
Conclusions: Escalating Raptopoulos CT grade is correlated with increasing probability of unresect-
ability and R1 resection.
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Introduction
Multiphase computed tomography angiography (CTA) is the
mainstay of pre-operative planning for patients with presumptive
pancreaticobiliary neoplasms. It predicts unresectability quite
well,1 allowing such patients to avoid an unnecessary laparotomy.
However, CTA has not been as successful in predicting actual
resectability, with reported predictive values of 45–79%.2–4 The
Raptopoulos CT grading system was developed to help predict
pre-operatively which of these tumours might be resectable.
Understanding that pancreaticobiliary tumours are often unresec-
table by virtue of intimate involvement with critical vasculature,
this five-point scale (Fig. 1) describes the radiographical relation-
ship of the mass to adjacent vessels (portal vein, superior mesen-
teric vein, superior mesenteric artery and celiac trunk).4 On
radiographical grounds, Grades 0 and 1 lesions are typically con-
sidered resectable, Grades 2 and 3 potentially resectable and Grade
4 unresectable.1,4 However, clinical experience has shown the
correlation between radiographical findings and intra-operative
findings/resectability to be imperfect.2–4
The terms ‘borderline resectable’ or ‘marginally resectable’ for
pancreaticobiliary malignancies have crept into the vernacular,
yet, as discussed during the 2008 AHPBA sponsored Consensus
Conference on Resectable and Borderline Resectable Pancreatic
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Cancer, a standardized definition does not exist.5 Terminology of
vascular involvement of these lesions is inconsistent and various
groups have put forth alternative definitions.3,5,6 The National
Comprehensive Cancer Network (NCCN) guidelines use ana-
tomic criteria to define anticipated resectability with particular
emphasis on vascular considerations.6 Although anatomic criteria
for resection have been fairly consistent in terms of delineating
such vascular involvement, the degree and severity of involvement
have varied in the literature. To further confuse the issue, the term
‘borderline resectable’ has also been applied to scenarios beyond
vascular relationships with the tumour, such as possible distant
disease identified by imaging and/or marginal medical status of
the patient.7,8 As a result, clinical experiences with this problem
are difficult to compare.
The importance of radiographical tumour characterization as it
affects operative inclusion or exclusion has not been well studied.
While resectability2–4 and margin status3,7,9 have been assessed with
respect to CT findings, other clinical outcomes including survival
have yet to be evaluated. In fact, the aforementioned AHPBA
Consensus Conference emphasized the need to study these impor-
tant clinical outcomes as they relate to pre-operative radiographi-
cal criteria.5 An understanding of these relationships would be
valuable in defining which tumours deserve an attempt at resec-
tion. The present study investigates the association between radio-
graphical tumour involvement with local vascular structures and
these important outcomes using an established and objective CT
grading scale. Through this analysis, outcomes and indications for
resection based on pre-operative imaging criteria might be better
refined.
Methods
Under the approval of an institutional Institutional Review Board,
a prospectively maintained pancreatic surgical database of pre-
sumptive pancreaticobiliary malignancy cases that were ultimately
operated upon between October 2001 and August 2008 was
reviewed. Patients were only included if their pre-operative CTA
had been performed locally and if curative resection was
attempted.All lesions that had a pre-operative working diagnosis of
presumed malignant potential irrespective of site were included.
Patients were excluded if they had pre-operative diagnoses of
high- or mid-duct cholangiocarcinoma, or small, radiographically
obvious neuroendocrine tumours where vascular invasion was
unlikely. Patients with cystic lesions were excluded with the excep-
tion of those with concerns for malignancy based on clinical
presentation (jaundice and weight loss), presence of solid compo-
nents on imaging, elevated serum tumour markers, or a suspi-
cious aspirate. Using CTA imaging, patients with obvious regional
or distant metastatic disease were also excluded.
Helical CTA was performed in each patient, using a multide-
tector (4–64 row) CT employing a bolus tracking technique as
previously described.4 Biphasic (arterial and portal venous) phase
Figure 1 Raptopoulos computed tomography (CT) grading system for Pancreaticobiliary Neoplasms. (A) Grade 0: no vascular involvement
with interposition of either pancreatic parenchyma or fat between the vessel and the tumour. (B) Grade 1: loss of the fat plane between the
tumour and vessel without vessel distortion. (C) Grade 2: slight flattening or indentation of vessel, or surrounding up to 2/3 the vessel
perimeter. (D) Grade 3: tumour extends around at least 2/3 of the vessel perimeter, changing its contour and narrowing the lumen; sometimes
referred to as the ‘teardrop sign’. (E) Grade 4: occlusion or obliteration of vessel without option for reconstruction
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high resolution scans were done using 0.5–1 mm collimation fol-
lowed by multiplanar reconstructions and expert 3-D imaging at
the imaging lab. These studies were interpreted by dedicated pan-
creatic radiologists for clinical care, and the CT grades were then
tabulated for the purpose of this study. The Raptopoulos grading
system is illustrated in Fig. 1 and details of each individual grade
are explained in the legend. This was originally devised for
tumours in the head of the pancreas, looking at vascular involve-
ment of the portal and superior mesenteric veins (SMV), and the
superior mesenteric artery (SMA). Its use has since been extended
and applied to the celiac axis, and to body/left-sided tumours in
proximity to the confluence and/or the celiac axis or SMA. For the
purpose of this study, venous involvement pertains to the SMV
and portal vein. Arterial involvement refers to the SMA, hepatic
artery or celiac trunk.
Further evaluation with staging laparoscopy +/- intra-
operative ultrasound was selectively applied for solid pancreatic
and biliary malignancies as previously described,10 with the excep-
tion of ampullary or duodenal lesions and in those patients in
which laparotomy would be required for palliation in the event
that resection was not possible. Pre-operative biopsy confirmation
of malignancy was not routinely obtained and neoadjuvant
chemoradiation therapy was never employed.
A standard pylorus-preserving pancreaticoduodenectomy was
performed as previously described, including skeletonization
of the SMA11. Vascular resection/reconstruction was performed
during trial dissection when tumour involvement of the vascula-
ture precluded safe and complete dissection of the portal-SMV
confluence or for limited segmental hepatic artery involvement.
Vascular resection was not technically feasible in the following
scenarios: an inability to obtain both proximal and distal control,
greater than short segment vascular encasement, peritumoral
fibrosis precluding appropriate identification/negotiation of the
portal canal, or the presence of extensive lymphatic involvement.
For left-sided tumours, local resection was performed as indi-
cated. For those patients who were deemed unresectable at lap-
arotomy a selective approach to palliative procedures as necessary
was applied.
Intra-operative frozen section analysis of the bile duct or pan-
creatic neck transection margin was employed selectively. Peri-
operative variables assessed included estimated blood loss, intra-
operative transfusion, operative time and whether or not portal-
superior mesenteric vein resection was performed. Extreme blood
loss was defined a priori as those patients whose estimated blood
loss was greater than one standard deviation above the mean.
Once resected, the specimen was marked intra-operatively iden-
tifying the following margins: bile duct, pancreatic transection
margin and SMA. A standardized pathological assessment was
performed by dedicated pancreatic pathologists. Margin status
was ascribed as follows: all margins devoid of tumour (R0), micro-
scopic tumour present at the margin(s) (R1) and gross residual
tumour as determined by the surgeon at the time of surgery (R2).
A reproducible post-operative Carepath for Pancreatic
Resection was followed.12 Post-operative data recorded included
major complications (as defined by the Clavien scale13) and hos-
pital stay. Peri-operative death was defined as death within 30 days
of the operation or at any point during the index hospitalization.
Survival information was obtained from our institutional cancer
registry and confirmed by the Social Security Death Index 6
months after accrual of the final patient.14
Table 1 Univariate analysis of pre-operative factors predicting
resection
Resected
(276)
Unresected
(117)
P-value
CT Grade <0.0001
0 209 (75.7) 41 (35.0)
1 39 (14.1) 16 (13.7)
2 22 (8.0) 33 (28.2)
3 6 (2.2) 27 (23.1)
Age 65 (27–85) 66 (33–84) 0.246
Sex 124M/152F 56M/ 61F 0.593
Presence of symptoms 234 (84.8) 110 (94.1) 0.011
Pre-operative diagnosis <0.0001
Pancreatic mass 192 (69.6) 106 (90.6)
Concerning cystic lesion 75 (27.2) 8 (6.8)
Other 9 (3.2) 3 (2.6)
Staging laparoscopy alone 61 (22.1) 65(55.6) <0.0001
Staging laparoscopy with
IOUS
25 (9.1) 32 (27.4) <0.0001
Table 2 Number of patients who were deemed unresectable (with reason) at laparotomy by CT grade
CT grade Total 0 1 2 3 P-value
n (%) (n = 393) (n = 250) (n = 55) (n = 55) (n = 33)
Unresectable 117 (29.8) 41 (16.4) 16 (29.1) 33 (60.0) 27
0.003
Metastatic disease 49 (12.5) 26 (10.4) 4 (7.3) 10 (18.2) 9
Vascular involvement 45 (11.5) 14 (5.6) 12 (21.8) 23 (41.8) 16
Othera 3 (0.8) 1 (0.4%) 0 0 2
aPhysiological instability, severe pancreatitis, hostile abdomen.
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Statistical analysis was performed using SAS version 9.1 to
obtain Kaplan–Meier survival curves. Fisher’s exact test, Kruskal–
Wallis, the log-rank test and Mann–Whitney U or Student’s t-test
were also used when appropriate. Data were checked for normal-
ity, and parametric or non-parametric tests were used as required.
Results with a P-value of 0.05 or less were considered significant.
Results
During the 7-year time period, 393 patients met inclusion criteria.
Of these, 250 (63.6%), 55 (14.0%), 55 (14.0%), 33 (8.4%) were
categorized as CT grade 0–3, respectively. In 143 (36.4%) patients,
the CT showed evidence of vascular involvement by the tumour.
In 97 (67.8%), 34 (23.8%), 12 (8.4%) patients this was venous
alone, venous and arterial or arterial alone, respectively.
Out of 126 patients undergoing staging laparoscopy, 32 (25.3%)
avoided further intervention, 15 (11.9%) required open staging
and/or biopsy (classified as non-therapeutic laparotomy) and 18
(14.3%) underwent palliative bypass. With respect to laparoscopic
intra-operative ultrasound (n = 57), 15 (26.3%) patients avoided
laparotomy, 7 (12.3%) had non-therapeutic laparotomy and 10
(17.5%) underwent palliative bypass. Therefore, staging laparos-
copy and intra-operative ultrasound allowed 47 (37.3%) patients
to avoid a non-therapeutic laparotomy.
During surgery, 276 (70.2%) patients underwent resection,
71 (18.1%) laparotomy only and 46 (11.7%) a palliative bypass.
Univariate analysis of factors predicting resection is shown in
Table 1. In multivariate regression analysis, higher CT grade (P <
0.001) and staging laparoscopy (P = 0.004) remained as indepen-
dent predictors of unresectablity. Vascular involvement as the
reason for unresectability was correlated with increasing CT grade
as shown in Table 2.
Peri-operative variables by CT grade for those patients who
underwent resection are shown in Table 3. Out of the eight
Table 3 Univariate analysis of peri-operative variables by CT grade for those patients who underwent resection
Peri-operative variable Total Grade 0 Grade 1 Grade 2 Grade 3 P-value
n (%), median (range) (n = 276) (209) (39) (22) (6)
Operation 0.078
Pancreaticoduodenectomy 196 139 32 19 6
(71) (66.5)
Left-sided pancreatectomy 61 55 5 1 0
(22.1) (26.3))
Othera 19 15 2 2 0
(6.9) (7.2)
Operative time (min) 383 368 422 383 453 0.006
43–681 133–681 43–635 243–662 363–669
Vascular resection/reconstruction 8 (2.9) 3 (1.4) 1 3 1
Blood loss (ml) 350 325 350 400 350 0.669
25–2500 25–2500 25–1000 150–1800 200–1900
Number of patients with extreme blood loss 32 21 5 5 1 0.604
(11.6) (10.0)
Number of patients transfused 37 29 3 4 1 0.563
(13.4) (13.9)
Number of patients with major complications 125 94 19 10 2 0.910
(45.2) (45.0)
Length of stay (days) 8 8 8 8 8 1.000
(1–67) (1–67) (5–28) (6–25) (7–9)
Peri-operative mortality 4 3 1 0 0
Histology 0.006
Pancreatic ductal adenocarcinoma 131 86 27 12 6
(47.5) (41.1)
Other malignancyb 53 6 4 3 0
(19.2) (2.9)
Benign neoplastic 60 50 3 7 0
(21.7) (23.9)
Benign non-neoplastic 32 27 5 0 0
(11.6) (12.9)
a7central pancreatectomy, 8 total pancreatectomy, 4 enucleations.
b24 ampullary, 11 endocrine, 7 cholangiocarcinoma, 3 duodenal, 2 solid pseudopapillary, 1 each of neuroendocrine, clear cell, GIST, mixed
ductal/endocrine, poorly differentiated unclear origin, IOPN.
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patients who underwent vascular reconstruction, four involved
the SMV, three the portal vein and one the hepatic artery. Univari-
ate analysis of factors predicting margin status is shown in Table 4.
Multivariate regression analysis identified only higher CT grade to
be a predictor of positive margins (P = 0.044). For those patients
with pancreatic ductal adenocarcinoma (Table 5), univariate
analysis confirmed increasing CT grade was significantly related
to resection margin status but not T or n stage. Locations of
positive margins are shown in Table 5.
Data regarding the use of adjuvant therapy were available
for 233 out of 301 patients with malignant diagnoses (by
intra-operative or other pathologic specimen). In those who
underwent resection, adjuvant therapy was administered to 80/99
(80.8%), 24/27, 10/13 and 5/5 patients with CT grade 0–3, respec-
tively,P = 0.593. Similarly for those who did not undergo resection
the corresponding figures for CT grade 0–3 were 22/25, 13/13,
25/25 and 15/18, respectively (P = 0.087).
The median follow-up was 11 months (0–85), and 168 (42.7%)
patients had died at the completion of the study. Kaplan–Meier
survival analyses was performed for patients with pancreatic
adenocarcinoma, demonstrating that there was no significant
difference in survival as CT grade increased (P = 0.232). Using
univariate analysis, age (P < 0.0001) and pathology (P < 0.009)
were significant variables. In multivariate regression analysis
considering all resected patients with pancreas cancer, significant
variables that remained were age (P = 0.003) and pathological
diagnosis (P < 0.0001).
Discussion
In the current era of high-quality imaging and safer post-
operative outcomes, resectability is better predicted than in the
past, but approximately a quarter of patients deemed eligible for
resection are still found to be unresectable at the time of surgery.1
Table 4 Univariate comparison of margin negative vs. margin positive patients
Margins negative (125) Margins positive (58) P-value
CT Grade 0.020
0 96 (76.8) 35 (60.3)
1 17 (13.6) 14 (24.1)
2 11 (8.8) 4 (6.9)
3 1 (0.8) 5 (8.7)
Age 67.5 67 0.651
39–85 39–83
Gender 55 (44.0) 24 (41.4) 0.739
Presence of symptoms 120 (96.0) 57 (98.3) 0.421
Pre-operative diagnosis 0.866
Pancreatic mass 111 (88.8) 50 (86.2)
Concerning cystic lesion 10 (8.0) 6 (10.3)
Other 4 (3.2) 2 (3.5)
Estimated blood loss (ml): 350 (100–2000) 350 (25–1900) 0.176
Operative time (min) 397 (43–520) 401 (152–722) 0.656
Staging laparoscopy alone 24 (19.2) 11(19.0) 0.970
Staging laparoscopy with IOUS 11 (8.8) 8 (13.8) 0.303
Type of operation 0.291
Pancreaticoduodenectomy 100 (80.0) 47 (81.0)
Left pancreatectomy 17 (13.6) 10 (17.2)
Other 8 (6.4) 1 (1.7)
Vascular resection/reconstruction 4 (3.2) 4 (6.7) 0.255
Pathology 0.014
PDAC 82 (65.6) 48 (82.8)
Other malignancy 43a 10b
Number of patients with major complications 59 (47.2) 32 (55.2) 0.316
Perioperative mortality 2 (1.6) 1 (1.7) 0.951
aAmpullary (22), cholangio (4), other (16).
bAmpullary (1), cholangio (3), other (6).
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Previous work by Raptopoulos and others1,4,15 has demon-
strated the important role of high-quality CTA imaging in guiding
operative decision-making for pancreatic resection. In the five-
point Raptopoulos scale, Grades 0 and 1, denoting no vascular
involvement and tumour/vessel abutment, respectively, have pre-
viously been considered resectable on radiographical grounds.
Grades 2 and 3 are determined to be potentially resectable. Finally,
Grade 4 lesions are deemed unresectable.1 The current study has
confirmed these findings, showing that an increasing CT grade is
associated with increasing probability of unresectability irrespec-
tive of underlying pathology. In addition, patients with a higher
CT grading are more likely to be unresectable as a result of vas-
cular invasion (Table 2). The fact that 10.4% of patients with CT
grade 0 had unresectable disease owing to low volume metastases,
while a further 5.6% were unresectable because of locally
advanced disease indicates the limitations of current cross-
sectional imaging and raises the issue of the role of laparoscopic
staging in such patients.
Several groups have advocated for the sole use of CT to guide
operative decision-making, stating that additional imaging
modalities and laparoscopy are superfluous in patients without
CT evidence of local vascular encroachment.2 Details of techni-
cal factors and image post-processing that create such quality CT
imaging as were used for this study and at other high-volume
pancreas centres have been previously established.16 Additionally,
House et al.3 report that pre-operative 3D-CT accurately pre-
dicted resectability for periampullary cancers in 98% of patients,
and for pancreatic cancer in 79% of patients. The margin-
negative resection rate was reported to be 86% and 73%, respec-
tively. Other groups have investigated the accuracy of PET and
PET/CT at predicting resectability (70 and 82%, respectively),17
utility of EUS9, or the additive value of CA19-9 to laparoscopy18
and intra-operative ultrasound.19 White et al. recently reported
that laparoscopy alone was useful, particularly when pre-
operative imaging was obtained outside of their institution.20
The present study has demonstrated that a higher percentage of
unresectable patients underwent both laparoscopy (55.6%) and
intra-operative ultrasound (37.2%), compared with its usage in
resectable patients. For both, the difference was statistically sig-
nificant in univariate analysis but only laparoscopy proved to be
a significant contributor in multivariate analysis. This likely
reflects some degree of bias resulting from a selective use of
these modalities, but also emphasizes those scenarios in which
staging with laparoscopy and/or ultrasound demonstrated meta-
static disease or confirmed vascular involvement that prevented
a laparotomy. As described above, a non-therapeutic laparotomy
was avoided in 32 (25.3%) patients with staging laparoscopy and
in 15 (11.9%) patients with ultrasound (although it was used
less frequently than laparoscopy alone). Further study is required
to better delineate the usage and the utility of ultrasound as a
modality in this setting.
Several groups have also described the relationship between
vascular involvement and positive margins.3,7 This has been con-
firmed by the present study. The positive margin rate for those
patients which were ultimately resected also increased as CT grade
increased. Even CT Grade 0 tumours ultimately had positive
margins 21% of the time. Previously, margin positivity has been
considered a predictor of poor prognosis.21–24 Yet, as discussed at
Table 5 Analysis of pathological variables by CT grade for patients with pancreatic adenocarcinoma
Total Grade 0 Grade 1 Grade 2 Grade 3 P
131 86 27 12 6
T 0.863
1 11 (8.4) 10 (11.6) 1 0 0
2 27 (20.6) 16 (18.6) 6 3 2
3 85 (64.9) 54 (62.8) 18 9 4
4 1 (0.7) 1 (1.2) 0 0 0
n 0.878
0 44 (33.6) 31 (36.0) 8 4 1
1a 33 (25.2) 21 (24.4) 7 4 1
1b 47 (35.9) 29 (33.7) 10 4 4
R0 84 (64.1) 58 (67.4) 13 9 1 0.021
Margins positive 47 27 14 3 5
Locations of positive marginsa
SMA 23 11 7 3 2
Pancreatic neck 17 6 6 1 4
Radial 15 10 4 0 1
CBD/duodenum 6 4 1 1 0
aIncludes multiple positive margins where applicable.
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the AHPBA sponsored 2008 Consensus Conference on Resectable
and Borderline Resectable Pancreatic Cancer, the actual relevance
of margins in pancreatic surgery is nebulous.25
Survival specifically for pancreatic adenocarcinoma patients
did not vary by CT grade but rather solely on age and pathology,
in multivariate analysis. Although higher grade lesions were less
likely to be resectable, when resection was accomplished, it was
generally done safely. Operative time was significantly related to
CT grade (longer in CT Grade 3), but there was no significant
increase in estimated blood loss, extreme blood loss, transfusions,
complications or death rates as grade increased (Table 3). There-
fore, these advanced-appearing lesions should not be categorically
excluded from an attempted resection although a higher incidence
of a positive margin is likely.
Although CT quality was considered state-of-the-art through-
out this contemporary series, advances in imaging certainly have
occurred over this period, possibly influencing the ability to
accurately grade tumours from the earlier portion of the study.
In addition, there is a probable selection bias when it comes to
advanced grade lesions (particularly CT Grade 3) which may be
precluded from surgical referral based on the practitioner’s
interpretation of radiographic reports of dubious resectability.
Furthermore, the authors have not commonly found the occa-
sion for vein resection in our practice. Of the 393 patients con-
sidered for potential resection, in only eight was it deemed that
vein resection/venorrhaphy was either indicated or technically
achievable. In the authors’ experience, a tumour can frequently
be negotiated off the confluence more often than predicted, thus
avoiding the need for vein resection. The overall 70% resectabil-
ity rate is generally in line with other published data26,27 and a
published series of vein resections show actual tumour involve-
ment of the vein in as few as 38% or as many as 78% of
specimens.28–32 Similarly, no patients who received neoadjuvant
therapy were included in this series. Although others7,8 have
reported neoadjuvant therapy as routine in their management of
these patients, there is not yet a good understanding of how to
reassess such patients after their treatment in terms of down-
staging, or how delaying the operation affects ultimate outcome.
An interesting question to evaluate would be if such a ‘down-
staging’ approach might regress tumours from higher to lower
Raptopoulos CT Grades and therefore afford fewer
positive margins, higher resectability rates and potentially better
survival.
By using objective criteria, rather than ambiguous nomencla-
ture (i.e. terms such as encroachment, encasement, infringement,
abutment and invasion), CTA grading is useful in predicting
tumour resectability of pancreaticobiliary neoplasms. With higher
degrees of vascular involvement, margins are more likely to be
positive and the resection is likely to take longer. Survival for
pancreas cancer does not depend on CT grade.
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